Results of a European Multicentre Study with Sandostatin® LAR® in Acromegalic Patients
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in Pituitary
- Vol. 1 (2) , 105-114
- https://doi.org/10.1023/a:1009980404404
Abstract
A European multicentre, open-label 12-month study with Sandostatin® LAR® administered intramuscularly at 4-week intervals was initiated in 151 acromegalics responsive to octreotide. All patients...Keywords
This publication has 21 references indexed in Scilit:
- Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide1Journal of Clinical Endocrinology & Metabolism, 1997
- Sandostatin LAR in Acromegalic Patients: Long Term TreatmentJournal of Clinical Endocrinology & Metabolism, 1997
- The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.Journal of Clinical Endocrinology & Metabolism, 1995
- Determinants of clinical outcome and survival in acromegalyClinical Endocrinology, 1994
- Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failureJournal of Neurosurgery, 1993
- Are Patients with Acromegaly at Increased Risk forNeoplasia¿*Journal of Clinical Endocrinology & Metabolism, 1991
- Ascertainment and natural history of treated acromegaly in Northern Ireland.1990
- Long Term Effects of Continuous Subcutaneous Infusion of the Somatostatin Analog Octreotide in the Treatment of AcromegalyJournal of Clinical Endocrinology & Metabolism, 1989
- Epidemiology and Long‐term Survival in Acromegaly: A Study of 166 Cases Diagnosed between 1955 and 1984Acta Medica Scandinavica, 1988
- CONTINUOUS SUBCUTANEOUS PUMP INFUSION OF SOMATOSTATIN ANALOGUE SMS 201‐995 VERSUS SUBCUTANEOUS INJECTION SCHEDULE IN ACROMEGALIC PATIENTSClinical Endocrinology, 1987